Norgine Pharmaceuticals Ltd
Norgine Pharmaceuticals Ltd is a privately held European specialty pharmaceutical company founded in 1906 that acquires, develops, and commercialises innovative drugs in gastroenterology, hepatology, and related therapy areas, reporting over €500 million in annual net product sales and serving roughly 25 million patients.
- Company typePrivate
- Founded1906
- HeadquartersNot specified
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Norgine Pharmaceuticals Ltd does
Norgine Pharmaceuticals Ltd is a European specialist pharmaceutical company founded in 1906 and headquartered in Harefield Ward, Hillingdon, London. The company focuses on gastroenterology and hepatology, with stated intent to expand into additional specialty therapy areas. It reports over €500 million in annual net product sales and treats approximately 25 million patients each year, supported by a workforce of more than 1,400 employees. Norgine remains privately held.
The company's business model centres on acquiring, developing, and commercialising innovative pharmaceutical products rather than performing discovery research at scale. It deploys capital into in-licensing, acquisition, and special-purpose vehicle (SPV) arrangements to bring specialty products into its portfolio, then commercialises them through an integrated European commercial infrastructure complemented by a global network of partnerships. This hybrid model — owned infrastructure in core European markets plus partnership-led distribution elsewhere — is the structural backbone of its go-to-market approach.
Revenue mechanics are driven by net product sales of approved specialty pharmaceuticals sold primarily into European healthcare systems (national health services, hospital systems, and payers). End-customer reach is broad at 25 million patients per year, but commercial economics depend on a concentrated set of in-market products and the regulatory and reimbursement environment of each European country. Norgine reinvests commercial proceeds into further product acquisition and development, which is the principal engine of long-term portfolio expansion.
Norgine Pharmaceuticals Ltd firmographics
Firmographics- Name
- Norgine Pharmaceuticals Ltd
- Legal name
- Norgine Pharmaceuticals Ltd
- Website
- https://norginepharmaceuticals.co.uk
- Company type
- Private
- Founded year
- 1906
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Norgine Pharmaceuticals Ltd is a privately held European specialty pharmaceutical company founded in 1906 that acquires, develops, and commercialises innovative drugs in gastroenterology, hepatology, and related therapy areas, reporting over €500 million in annual net product sales and serving roughly 25 million patients.
- Ownership category
- akta.pro rank
Norgine Pharmaceuticals Ltd industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
Keywords
Where Norgine Pharmaceuticals Ltd is headquartered
LocationHeadquarters
- HQ city
- Not specified
Offices1 record
Markets served
Norgine Pharmaceuticals Ltd business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations
Revenue model
- Pharmaceutical product sales: Net product sales from commercialising innovative pharmaceutical products across specialist therapy areas including gastroenterology and hepatology. Revenue is generated through product commercialisation across European markets with global partnership networks.
Go-to-market motion1 record
Distribution channels1 record
Norgine Pharmaceuticals Ltd product offering
Product offeringCore offering
Norgine acquires, develops, and commercialises innovative pharmaceutical products across specialist therapy areas—primarily gastroenterology and hepatology. The company operates an integrated European commercial infrastructure supported by a global network of partnerships (including licensing, acquisition, and SPV arrangements) to bring transformative medicines to patients.
Product overview
Norgine is a European specialist pharmaceutical company founded in 1906 that acquires, develops, and commercialises innovative pharmaceutical products. The company operates across multiple specialist therapy areas including gastroenterology and hepatology, with over €500 million in net product sales. Norgine works with partners through various arrangements including licensing, acquisition, and special purpose vehicles (SPV) to bring transformative medicines to patients, serving approximately 25 million patients worldwide annually.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Helps 25 million patients worldwide every year
- +1 more outcomes
Companies that use Norgine Pharmaceuticals Ltd
Customer profileSegments1 record
Ideal customer profiles2 records
Norgine Pharmaceuticals Ltd technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Norgine Pharmaceuticals Ltd partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Various global partnership networkcoreNorgine operates with a strong global network of partnerships. The company partners in multiple ways including licensing, acquisition, and special purpose vehicle (SPV) arrangements. This partnership network enables the acquisition, development and commercialisation of innovative products.
Scale indicators4 records
Recent moves4 records
Expansion highlights5 records
Norgine Pharmaceuticals Ltd competitors and assessment
Company assessmentDirect peers
- Dr. Falk Pharma: Privately held European specialty pharmaceutical company headquartered in Germany with a primary focus on gastroenterology and hepatology, closely aligned with Norgine's therapeutic specialisation and European commercial orientation.
- Tillotts Pharma: Specialty pharmaceutical company focused on gastroenterology products across European markets, part of the Zeria Group; comparable to Norgine in therapeutic focus and European specialist commercial model.
Broad incumbents
- Almirall: Spanish specialty pharmaceutical company focused on dermatology and other specialty areas with European commercial infrastructure; comparable in the European specialty pharma business model though differentiated by primary therapy focus.
- Swedish Orphan Biovitrum (Sobi): European-headquartered specialty pharmaceutical company with strong rare disease and specialty focus; comparable in the European specialty pharma operating model though concentrated in different therapeutic areas.
- Recordati: Italian-headquartered specialty pharmaceutical group with a European presence and portfolio spanning multiple therapeutic areas including gastroenterology; broader than Norgine but overlapping in specialty pharma business model and European reach.
- Ipsen: France-based global specialty pharmaceutical company with presence in gastroenterology and other specialty therapy areas; broader portfolio and global reach make it a larger-scale incumbent in Norgine's specialist space.
Peers
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Norgine Pharmaceuticals Ltd social profiles
Digital presenceNorgine Pharmaceuticals Ltd financial estimates
Financial estimateRevenue estimate
Valuation estimate
Norgine Pharmaceuticals Ltd leadership team
Management profileNumber of profiles
Norgine Pharmaceuticals Ltd funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Norgine Pharmaceuticals Ltd M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Norgine Pharmaceuticals Ltd
What does Norgine Pharmaceuticals Ltd do?
Norgine acquires, develops, and commercialises innovative pharmaceutical products across specialist therapy areas—primarily gastroenterology and hepatology. The company operates an integrated European commercial infrastructure supported by a global network of partnerships (including licensing, acquisition, and SPV arrangements) to bring transformative medicines to patients.
Is Norgine Pharmaceuticals Ltd a public or private company?
Norgine Pharmaceuticals Ltd is a private company. It is classified as unknown and is currently operating.
When was Norgine Pharmaceuticals Ltd founded?
Norgine Pharmaceuticals Ltd was founded in 1906. It employs 11 to 50 people.
Where is Norgine Pharmaceuticals Ltd based?
Norgine Pharmaceuticals Ltd is headquartered in Not specified.
How does Norgine Pharmaceuticals Ltd make money?
One revenue line is on record: pharmaceutical product sales.
Who are Norgine Pharmaceuticals Ltd's main competitors?
Direct peers on record are Dr. Falk Pharma and Tillotts Pharma. Broad incumbents are Almirall, Swedish Orphan Biovitrum (Sobi), Recordati and Ipsen. Intercept Pharmaceuticals is listed as a peer.
Does Norgine Pharmaceuticals Ltd have an API?
No public API is recorded for Norgine Pharmaceuticals Ltd.
What industry is Norgine Pharmaceuticals Ltd in?
Norgine Pharmaceuticals Ltd's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.